Exelixis Inc (NASDAQ: EXEL) is a oncology-focused biopharmaceutical company that discovers, develops, and commercializes cancer therapies. The filing excerpts provided do not contain sufficient detail to describe Exelixis's revenue model, product portfolio, competitive position, geographic footprint, leadership, or financial metrics beyond its SEC registration status. Based solely on the 10-K filed February 10, 2026 (accession 000093976726000021), Exelixis is incorporated and files as a well-known seasoned issuer under the Securities Exchange Act of 1934, with securities registered under Section 12(b) of the Act and traded under the ticker EXEL.

Source: SEC 10-K, filed 2026-02-10

Industry: Biological Products, (No Diagnostic Substances) Peers: Cerevel Therapeutics Holdings, Inc. Cytokinetics Inc Exact Sciences Corp Global Blood Therapeutics, Inc. Halozyme Therapeutics Inc Ionis Pharmaceuticals Inc Natera Inc